A Prospective, Open-Label, Non-Randomized, Multi-Center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients
Latest Information Update: 07 Apr 2022
Price :
$35 *
At a glance
- Drugs Voriconazole (Primary) ; Voriconazole (Primary)
- Indications Aspergillosis; Invasive bronchopulmonary aspergillosis
- Focus Adverse reactions
- Sponsors Pfizer
- 06 Apr 2022 This trial has been completed in Netherland (Global end date: 15/05/2013), according to European Clinical Trials Database record.
- 20 Dec 2021 This trial has been completed in Hungary (Global end date: 15 May 2013)
- 18 Oct 2016 New trial record